← Eichor
Study identifier: NCT05686226 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Condition: Cervical Cancer · Throat Cancer · Oropharynx Cancer  ·  Sponsor: Christian Hinrichs

PhasePhase 2
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers. Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin. Clinical response to treatment will be determined.

This description comes directly from the study's public registry record.

Talk to the study team

Tobi Adewale  ·  732-710-2406  ·  olutobi@cinj.rutgers.edu

Always discuss trial participation with your own doctor first.

Locations (3)

National Institutes of Health Clinical CenterBethesda, Maryland, United StatesRecruiting
Rutgers Cancer InstituteNew Brunswick, New Jersey, United StatesRecruiting
RWJBarnabas Health - Robert Wood Johnson University HospitalNew Brunswick, New Jersey, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05686226